InnovAge Holding Corp. INNV R2KPHARMA
Company Overview
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. It serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 1989 and is headquartered in Denver, Colorado.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.36.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jun 2025 Revenue of $853.70M (+11.8% YoY); net profit $-30.31M.
- Trailing 12 Months Year-on-year growth — revenue +15.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.9%, profit CAGR -121.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.91% |
| 1 Year: | 15.50% |
Compounded Profit Growth
| 5 Years: | -121.62% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +193.72% |
| 6 Months: | +19.71% |
| 3 Months: | +47.26% |
| 1 Month: | -2.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -121.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INNV InnovAge Holding Corp. R2KPHARMA | 10.75 | -134.38 | $1.46B | 0.00% | -4.46% | -5.88% | 6.91% | -121.62% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 144.77M | 152.57M | 157.31M | 156.31M | 173.07M | 175.35M | 177.36M | 171.22M | 167.46M | 172.54M | 182.49M | 188.90M | 193.07M | 205.14M | - | 218.14M | 221.42M | 236.10M | 239.71M | 251.94M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 177.40M | 180.13M | 184.75M | 186.88M | 190.92M |
| Gross Profit | - | - | - | - | - | - | 28.00M | 21.42M | 22.57M | 28.79M | 27.88M | 33.61M | 34.00M | 34.54M | - | 40.75M | 41.29M | 51.36M | 52.83M | 61.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.91M | 38.32M | 42.96M | 39.56M | 90.10M |
| Operating Income | 12.97M | -38.18M | 20.54M | -5.37M | 11.66M | 2.95M | -6.67M | -16.60M | -13.68M | -8.17M | -10.72M | -1.78M | -5.79M | -4.90M | - | -10.16M | 2.97M | 8.39M | 13.26M | -29.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.51M | 85.00K | 14.25M | 18.58M | -23.96M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.16M | 893.00K | 1.25M | 1.25M | 988.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.06M | -4.20M | 7.92M | 12.46M | -29.77M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.00K | 807.00K | 247.00K | 651.00K | 167.00K |
| Net Income | 8.14M | -49.65M | 9.71M | -10.51M | 7.69M | 1.32M | -2.82M | -13.07M | -9.79M | -6.63M | -10.30M | -3.45M | -5.89M | -4.93M | - | -11.38M | -785.00K | 8.02M | 10.62M | -29.46M |
| Diluted EPS | 0.06 | -0.41 | 0.08 | -0.09 | 0.06 | 0.01 | -0.02 | -0.10 | -0.07 | -0.05 | -0.08 | -0.03 | -0.04 | -0.04 | - | -0.08 | -0.01 | 0.06 | 0.08 | -0.22 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 567.19M | 637.80M | 698.64M | 688.09M | 763.86M | 853.70M |
| Cost of Revenue | - | - | 563.27M | 586.80M | 631.79M | 700.06M |
| Gross Profit | - | - | 135.37M | 101.29M | 132.06M | 153.64M |
| Operating Expenses | - | - | 139.78M | 150.68M | 155.24M | 169.78M |
| Operating Income | 50.93M | -12.34M | -4.41M | -49.40M | -23.18M | -16.15M |
| EBITDA | - | - | 9.21M | -33.85M | 1.15M | -9.90M |
| Interest Expense | - | - | 2.53M | 1.52M | 4.02M | 4.61M |
| Pretax Income | - | - | -7.24M | -50.79M | -21.82M | -34.03M |
| Tax Provision | - | - | 723.00K | -7.24M | 1.40M | 1.32M |
| Net Income | 26.28M | -43.99M | -6.52M | -40.67M | -21.34M | -30.31M |
| Diluted EPS | 0.19 | -0.36 | -0.05 | -0.30 | -0.16 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 409.63M | 531.75M | 555.60M | 567.36M | 547.66M | 526.85M |
| Total Equity | - | 81.44M | 101.02M | 334.56M | 332.36M | 296.30M | 269.26M | 234.97M |
| Cash & Equivalents | 9.00M | - | 112.90M | 201.47M | 184.43M | 127.25M | 56.95M | 64.13M |
| Long Term Debt | - | - | 210.43M | 71.57M | 68.21M | 64.84M | 61.48M | 57.46M |
| Total Liabilities | - | - | 301.88M | 173.79M | 201.85M | 252.56M | 247.85M | 263.94M |
| Current Liabilities | - | - | 76.63M | 78.56M | 105.31M | 148.45M | 138.60M | 164.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 43.83M | -7.55M | 27.30M | 20.24M | -36.90M | 32.87M |
| Investing Cash Flow | -11.69M | -19.54M | -40.24M | -69.52M | -26.37M | -5.55M |
| Financing Cash Flow | 21.23M | 116.22M | -6.32M | -7.90M | -7.03M | -19.08M |
| Capital Expenditure | -11.84M | -17.54M | -38.24M | -23.35M | -7.91M | -6.26M |
| Free Cash Flow | 31.98M | -25.09M | -10.94M | -3.12M | -44.81M | 26.60M |
| Share Buybacks | - | 77.60M | - | - | - | - |
| Dividends Paid | - | 9.50M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 19.4% | 14.7% | 17.3% | 18.0% |
| Operating Margin % | 9.0% | -1.9% | -0.6% | -7.2% | -3.0% | -1.9% |
| Net Margin % | 4.6% | -6.9% | -0.9% | -5.9% | -2.8% | -3.6% |
| ROE % | 26.0% | -13.1% | -2.0% | -13.7% | -7.9% | -12.9% |
| ROCE % | 15.3% | -2.7% | -1.0% | -11.8% | -5.7% | -4.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 4.51% | 6.12M | $66.51M |
| 2 | Federated Hermes, Inc. | 1.40% | 1.90M | $20.67M |
| 3 | Blackrock Inc. | 1.10% | 1.49M | $16.18M |
| 4 | Vanguard Capital Management LLC | 0.69% | 935.26K | $10.16M |
| 5 | Arrowstreet Capital, Limited Partnership | 0.49% | 668.74K | $7.26M |
| 6 | Algert Global, LLC | 0.46% | 630.52K | $6.85M |
| 7 | Geode Capital Management, LLC | 0.44% | 602.13K | $6.54M |
| 8 | State Street Corporation | 0.34% | 461.66K | $5.01M |
| 9 | Dimensional Fund Advisors LP | 0.32% | 439.96K | $4.78M |
| 10 | Acadian Asset Management. LLC | 0.29% | 390.85K | $4.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INNV
Why (INNV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQYVNEc25mb0JINFhPeEZTbFdpV3lKbHFqSk9BZ3ZSRnc0dGFRUFZIajNCaWJlamZKcTZLQWgtWk13LWY4VjR4anczSHcyNUtYdG5MWW1uMnBSQXFiRHFjd1VfWTFlOXVydV80NFowM1FtWDFwa09WZGpGRG9uMXR5V2prWk41N19FOEVwVG…
InnovAge Holding Corp. (INNV) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSlkzRklWOFRjWnUtbUo5aWxQSzIzV2xGc2pYdW0xYU9YWXBldktwdmN3SS1lTENXaEdxb1Q4ckJsc25zejZhQzlyVG5aSVZ1amcyTVNDcnpvb2oxX21pTUxBTXF5dnoySk53WWw1VUNJVVVlalFXWkVfX0tCMXZuYUl1SVNqMEJBZE9TSX…
BlackRock Inc. Takes Position in InnovAge Holding Corp. $INNV - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPM0dpaXNaSXIxYWJ1TjBaTDI3MXF1bF8tNm5LSnhVSHpZSFpzT1RSNFJueDQ0VzNnck1EN3FtT2ZrbUl1aGZFS0tKeHZOWHZGNXVyeEYzbElMZUkzMDMtYndqc3diMndTUjlLb0M3UWFpeDRhMExUZDVKck5rVTF6a2JtVjAwZXFDNm9tMk…
InnovAge stock holds after earnings call calendar points to September 8 - ad-hoc-news.de
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxORE9PeXUzbHlDLVE2UkVxN1dSeXZOQkh4N2kzMUZqa3d6ay1jbGtsRkN5WkZGenBhTWd6WUFSY1M1T0QxaVFJYm81OXdxTDJvTzUyRUdEbERDWV9tdVM5QlBnQnJmYW9wSWxUbkVMeGhESVBBcVVDTzVKcWxWLXdfRzA5Mm5tVmJDRU0ySz…
Down 28%, Is InnovAge Stock a Buy Now? - Trefis
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxObzE5UG9zQ05nYlhMOXQzUjl5YVhRQWlPMF9jTXFHUUdpTUJFVEUzcm9seU1QYnd1czRWYjJsRWhOc19FZ1Frc2Q5NDcxa3JZa0RCRVFFbXV2dGI3WFY0cXJRVC1HMnAzdTdiejdnM1BFTTY2ZkVLZHRTVWp2OXBTenBwZHZLeXVDS01CWH…
InnovAge: A Real Turnaround, But The Stock Now Trades Above Every Analyst Target - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaTBEZEpYdmpMM3VzdWRVTmNVT3RUbkY3TFBOVnU0LXVxak1YT0VNTWYxZHEyd193R01MZFlRbXo2VnU3Ukt6Uk51VkdDQTItR3BoMjgzSlp2ajBJUnhUcUZ4TmIwY0lHN0s3R1RqbUlVVVlsNjRDVDczUmxLLVZiZlVYbXRMWFpTQkNuNm…
INNV — Frequently Asked Questions
What is the current share price of InnovAge Holding Corp. (INNV)?
As of 2026-09-07 16:24 PDT, InnovAge Holding Corp. (INNV) trades at $10.75 on NasdaqGS. Its 52-week range is $3.43 to $12.11.
What is the market capitalisation of INNV?
InnovAge Holding Corp. (INNV) has a market capitalisation of $1.46B on NasdaqGS.
What is the P/E ratio of INNV?
INNV trades at a trailing price-to-earnings (P/E) ratio of -134.38. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.62.
What is the return on equity (ROE) of INNV?
INNV has a return on equity (ROE) of -5.88%. Its return on capital employed (ROCE) is -4.46%.
Is INNV a good stock to buy?
This page provides a data-driven analysis of InnovAge Holding Corp. (INNV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.